Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute corona...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2018
|
| Sorozat: | NEW ENGLAND JOURNAL OF MEDICINE
379 No. 22 |
| Tárgyszavak: | |
| doi: | 10.1056/NEJMoa1801174 |
| mtmt: | 32662628 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/27059 |